Medika d.d. (ZSE:MDKA)
Croatia · Delayed Price · Currency is HRK · Price in EUR 5,500.00
+100.00 (1.85%)
At close: Aug 1, 2025
CTI BioPharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 882.87 | 826.32 | 745.79 | 628.1 | 549.59 | 528.45 | Upgrade |
Other Revenue | 7.25 | 6.12 | 4.69 | - | - | - | Upgrade |
| 890.13 | 832.45 | 750.49 | 628.1 | 549.59 | 528.45 | Upgrade | |
Revenue Growth (YoY) | 12.23% | 10.92% | 19.49% | 14.28% | 4.00% | 7.83% | Upgrade |
Cost of Revenue | 821.83 | 766.87 | 690.85 | 577.1 | 504.03 | 486.32 | Upgrade |
Gross Profit | 68.3 | 65.57 | 59.64 | 51 | 45.56 | 42.13 | Upgrade |
Selling, General & Admin | 27.46 | 26.21 | 22.93 | 20.62 | 19.18 | 17.16 | Upgrade |
Other Operating Expenses | 12.49 | 11.39 | 10.05 | 9.04 | 7.8 | 7.39 | Upgrade |
Operating Expenses | 45.24 | 42.38 | 37.31 | 33.69 | 30.87 | 28.1 | Upgrade |
Operating Income | 23.06 | 23.19 | 22.33 | 17.31 | 14.69 | 14.03 | Upgrade |
Interest Expense | -2.21 | -2 | -1.73 | -0.37 | -0.59 | -0.92 | Upgrade |
Interest & Investment Income | 6.72 | 3 | 2.28 | 2.65 | 1.4 | 0.23 | Upgrade |
Earnings From Equity Investments | 0.58 | 0.51 | 0.43 | 0.43 | 0.38 | 0.3 | Upgrade |
Currency Exchange Gain (Loss) | -0.01 | -0.01 | -0.01 | -0.28 | 0.13 | -1.26 | Upgrade |
EBT Excluding Unusual Items | 28.14 | 24.69 | 23.3 | 19.74 | 16 | 12.39 | Upgrade |
Gain (Loss) on Sale of Assets | 0.14 | 0.14 | 1.08 | 0.9 | 0.08 | 0.03 | Upgrade |
Legal Settlements | - | - | - | - | - | -0 | Upgrade |
Pretax Income | 28.28 | 24.83 | 24.37 | 20.64 | 16.08 | 12.42 | Upgrade |
Income Tax Expense | 5.12 | 4.52 | 4.29 | 5.15 | 2.84 | 2.24 | Upgrade |
Net Income | 23.16 | 20.31 | 20.08 | 15.5 | 13.24 | 10.18 | Upgrade |
Net Income to Common | 23.16 | 20.31 | 20.08 | 15.5 | 13.24 | 10.18 | Upgrade |
Net Income Growth | 13.06% | 1.15% | 29.59% | 17.03% | 30.03% | 4.11% | Upgrade |
Shares Outstanding (Basic) | - | 0 | 0 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | - | 0 | 0 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | - | - | - | 2.56% | 3.59% | - | Upgrade |
EPS (Basic) | - | 701.49 | 693.51 | 535.16 | 468.99 | 373.62 | Upgrade |
EPS (Diluted) | - | 701.49 | 693.51 | 535.16 | 468.99 | 373.62 | Upgrade |
EPS Growth | - | 1.15% | 29.59% | 14.11% | 25.53% | 4.11% | Upgrade |
Free Cash Flow | 10.72 | -34.56 | 19.58 | 7.33 | 35.88 | 13.03 | Upgrade |
Free Cash Flow Per Share | - | -1193.44 | 676.38 | 253.26 | 1270.88 | 477.92 | Upgrade |
Dividend Per Share | - | - | 200.000 | 215.000 | 186.284 | 185.440 | Upgrade |
Dividend Growth | - | - | -6.98% | 15.42% | 0.46% | 4.54% | Upgrade |
Gross Margin | 7.67% | 7.88% | 7.95% | 8.12% | 8.29% | 7.97% | Upgrade |
Operating Margin | 2.59% | 2.79% | 2.98% | 2.76% | 2.67% | 2.66% | Upgrade |
Profit Margin | 2.60% | 2.44% | 2.68% | 2.47% | 2.41% | 1.93% | Upgrade |
Free Cash Flow Margin | 1.21% | -4.15% | 2.61% | 1.17% | 6.53% | 2.46% | Upgrade |
EBITDA | 25.64 | 25.26 | 24.09 | 19.36 | 16.62 | 15.8 | Upgrade |
EBITDA Margin | 2.88% | 3.03% | 3.21% | 3.08% | 3.02% | 2.99% | Upgrade |
D&A For EBITDA | 2.57 | 2.07 | 1.75 | 2.05 | 1.93 | 1.77 | Upgrade |
EBIT | 23.06 | 23.19 | 22.33 | 17.31 | 14.69 | 14.03 | Upgrade |
EBIT Margin | 2.59% | 2.79% | 2.98% | 2.76% | 2.67% | 2.66% | Upgrade |
Effective Tax Rate | 18.11% | 18.20% | 17.62% | 24.93% | 17.66% | 18.01% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.